Recombinant antibodies in the scFv-format are used in many novel and highly efficient cancer therapies such as CAR-T cells and bispecfic antibodies. However, scFv antibodies often suffer from poor experssion levels and a high tendency to aggregate.

Opti-mAb is a new format for scFv-antibodies developed by AAX Biotech that dramatically increases expression levels and removes aggregation tendencies. Using Opti-mAb accelerates drug development and increase the efficacy of therapies.

Please contact us to learn more: info@aaxbiotech.com